SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.
Location: United States, Massachusetts, Bedford
Employees: 11-50
Total raised: $63.2M
Founded date: 2017
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.09.2024 | Series B | $50M | - |
| 02.02.2021 | Series A | $13.2M | - |
Mentions in press and media 7
| Date | Title | Description |
| 13.09.2024 | SpectraWAVE: $50 Million (Series B) Raised To Advance HyperVue Imaging System | SpectraWAVE., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), announced a $50 million Series B funding round led by Johnson & Johnson Innovation – JJDC and joine... |
| 11.09.2024 | SpectraWAVE Raises $50M in Series B Financing | SpectraWAVE, Inc., a Bedford, MA-based medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), raised $50M in Series B funding. The round was led by Johnson & Johnson Inno... |
| 11.09.2024 | SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System | BEDFORD, Mass.--(BUSINESS WIRE)--SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson &... |
| 20.09.2023 | SpectraWAVE Secures 510(k) Clearance to Add Saline Imaging and Expanded Artificial Intelligence Features to the HyperVue Imaging System | — Next Generation DeepOCT and Near Infrared Spectroscopy Intravascular Imaging System Now Includes Expanded Toolkit to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab — SpectraWAVE, a medical imaging company focused on ... |
| 03.03.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 3rd March 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 02.03.2023 | SpectraWAVE Secures 510(k) Clearance of HyperVue Intravascular Imaging System | SpectraWAVE, a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), announced Food and Drug Administration (FDA) 510(k) clearance of their flagship intravascular imaging sy... |
| - | Spectrawave | “Image without compromise: SpectraWAVE's flagship state-of-the-art intravascular imaging system is designed to help interventional cardiologists optimize PCI ...” |